

Draft Genome Sequence of Israeli Outbreak-Associated Vibrio vulnificus Biotype 3 Clinical Isolate BAA87

Kelsey E. Phillips,^a Matthew J. Schipma,^b Karla J. F. Satchell^a

Department of Microbiology-Immunology^a and Next-Generation Sequencing Core Facility,^b Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

Vibrio vulnificus is a seafood-associated pathogen that causes severe wound and intestinal infections. Biotype 3 of *V. vulnificus* emerged in 1996 as the cause of an Israeli outbreak associated with the handling of infected tilapia. Here, we describe the whole-genome sequence of the ATCC biotype 3 clinical isolate BAA87 (CDC9530-96).

Received 5 February 2014 Accepted 27 February 2014 Published 20 March 2014

Citation Phillips KE, Schipma MJ, Satchell KJF. 2014. Draft genome sequence of Israeli outbreak-associated Vibrio vulnificus biotype 3 clinical isolate BAA87. Genome Announc. 2(2):e00032-14. doi:10.1128/genomeA.00032-14.

Copyright © 2014 Phillips et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license.

Address correspondence to Karla J. F. Satchell, k-satchell@northwestern.edu.

ibrio vulnificus is a Gram-negative bacterial pathogen found in coastal waters and causes gastroenteritis, primary septicemia, and necrotizing fasciitis in humans. The mortality rates for primary sepsis and wound infection are 50% and 15%, respectively, and the annual incidence of infections is increasing with climate change (1–4). The presence of V. vulnificus in oysters and other shellfish within coastal waters poses a large risk to the humans that handle them, and thus the characterization of this pathogen is critical (5). Strains have previously been classified as either biotype 1 (BT1), which is most commonly associated with clinical infections, or biotype 2 (BT2), which causes infections in eels (6-8). However, between 1996 and 1999, an outbreak caused by V. vulnificus of the biotype 3 (BT3) lineage resulted in wound infections due to the handling of infected tilapia (9). Biotype 3 strains now cause wound infections in handlers of fish from the seas of Israel, with a death rate of 10% and survivors experiencing severe morbidity (10). Due to the sudden emergence and clonality of the Israeli BT3 strains (11), it is hypothesized that this is a newly emerged pathogen, and thus further investigation into the BT3 genome is pertinent in order to determine how the genomic content may affect disease progression.

In this paper, we describe the draft genome sequence of the clinical isolate V. vulnificus strain ATCC BAA87 (CDC9530-96), which was isolated from a patient wound during the original Israel epidemic in 1996. A total of 53.5 ng/ μ l of genomic DNA was extracted using the Qiagen DNeasy genomic DNA prep for Gramnegative bacterial cultures, according to the manufacturer's instructions. The DNA library was generated by the Northwestern University Genomics Core Facility and subsequently sequenced using the Life Technologies Ion Torrent PGM technology, specifically the 318 Chip paired with a 400-bp library. The genome was assembled using Newbler (GS de novo Assembler version 2.7) from 454 Life Sciences, with 1,022,286 total reads generating 218 contigs from 400-bp trimmed reads. The genome was aligned to V. vulnificus BT3 environmental isolate VVyb1(BT3) (12) using Torrent Mapper (TMAP) version 3.4.1. BAA87 has a 97.5% alignment to the reference genome, with an average coverage of $52 \times$. The assembled genome was annotated using the Rapid Annotations using Subsystems Technology (RAST), a SEED-based prokaryotic genome annotation service (13).

Nucleotide sequence accession numbers. The whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession no. JDSE00000000. The version described in this paper is version JSDE00000000.1.

ACKNOWLEDGMENTS

We thank Mark Mandel for technical advice and the Northwestern University Genomics Core Facility for library preparation and whole-genome sequencing.

This work was supported by an Investigators in the Pathogenesis of Infectious Diseases Award from the Burroughs Wellcome Fund, NIAID grants RO1 AI092825 and AI098369, and the Northwestern Medicine Catalyst Fund.

REFERENCES

- Baker-Austin C, Stockley L, Rangdale R, Martinez-Urtaza J. 2010. Environmental occurrence and clinical impact of *Vibrio vulnificus* and *Vibrio parahaemolyticus*: a European perspective. Environ. Microbiol. Rep. 2:7–18. http://dx.doi.org/10.1111/j.1758-2229.2009.00096.x.
- Baker-Austin C, Trinanes JA, Taylor NGH, Hartnell R, Siitonen A, Martinez-Urtaza J. 2013. Emerging *Vibrio* risk at high latitudes in response to ocean warming. Nat. Clim. Change 3:73–77.
- Newton A, Kendall M, Vugia DJ, Henao OL, Mahon BE. 2012. Increasing rates of vibriosis in the United States, 1996–2010: review of surveillance data from 2 systems. Clin. Infect. Dis. 54(Suppl 5):S391–S395. http: //dx.doi.org/10.1093/cid/cis243.
- Paz S, Bisharat N, Paz E, Kidar O, Cohen D. 2007. Climate change and the emergence of *Vibrio vulnificus* disease in Israel. Environ. Res. 103: 390–396. http://dx.doi.org/10.1016/j.envres.2006.07.002.
- Froelich B, Oliver JD. 2013. The interactions of Vibrio vulnificus and the oyster Crassostrea virginica. Microb. Ecol. 65:807–816. http://dx.doi.org/ 10.1007/s00248-012-0162-3.
- Amaro C, Biosca EG. 1996. Vibrio vulnificus biotype 2, pathogenic for eels, is also an opportunistic pathogen for humans. Appl. Environ. Microbiol. 62:1454–1457.
- Jones MK, Oliver JD. 2009. Vibrio vulnificus: disease and pathogenesis. Infect. Immun. 77:1723–1733. http://dx.doi.org/10.1128/IAI.01046-08.
- Tison DL, Nishibuchi M, Greenwood JD, Seidler RJ. 1982. Vibrio vulnificus biogroup 2: new biogroup pathogenic for eels. Appl. Environ. Microbiol. 44:640–646.
- 9. Bisharat N, Agmon V, Finkelstein R, Raz R, Ben-Dror G, Lerner L, Soboh

S, Colodner R, Cameron DN, Wykstra DL, Swerdlow DL, Farmer JJ, III. 1999. Clinical, epidemiological, and microbiological features of *Vibrio vulnificus* biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel. Israel Vibrio Study Group. Lancet **354**:1421–1424.

- Zaidenstein R, Sadik C, Lerner L, Valinsky L, Kopelowitz J, Yishai R, Agmon V, Parsons M, Bopp C, Weinberger M. 2008. Clinical characteristics and molecular subtyping of *Vibrio vulnificus* illnesses, Israel. Emerg. Infect. Dis. 14:1875–1882. http://dx.doi.org/10.3201/eid1412.080499.
- 11. Bisharat N, Cohen DI, Harding RM, Falush D, Crook DW, Peto T, Maiden MC. 2005. Hybrid Vibrio vulnificus. Emerg. Infect. Dis. 11:30–35. http://dx.doi.org/10.3201/eid1101.040440.
- Danin-Poleg Y, Elgavish S, Raz N, Efimov V, Kashi Y. 2013. Genome sequence of the pathogenic bacterium *Vibrio vulnificus* biotype 3. Genome Announc. 1(2):e00136-13. http://dx.doi.org/10.1128/genomeA. 00136-13.
- 13. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST server: Rapid Annotations using Subsystems Technology. BMC Genomics 9:75. http://dx.doi.org/10.1186 /1471-2164-9-75.